Please assess the completion status of the following clinical trial:

Trial Title: Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of both sexes, aged between 18 and 50 years.~* Subjects who have undergone a detailed medical history, clinical checkup and are in good health.~* Subjects who have understood the purpose of the study and have freely signed the informed consent.~* Subjects who consent with repeated blood samples taking.~* Subjects who will be available to perform the follow-up visits, are reachable by telephone, and are able to complete the diary cards throughout the study duration.~* For female volunteers, a negative pregnancy test and an adequate contraception throughout the study duration.~Exclusion Criteria:~* Known history of recent contact Shigella infection or long-term residence in a Shigella endemic region (Central America, Africa, and India).~* Known history of hypersensitivity to any component of the vaccine (EPA; Aluminium Hydroxide).~* Subjects with compromised immune system.~* Family history of congenital or hereditary immunodeficiency.~* Chronic administration of an immunosuppressive treatment or other immune-modifying drugs within six months prior to the first vaccine dose.~* Subjects that received any other vaccine during the 1 month preceding the 1st injection and may receive before the 2nd injection. If the subject needs to be vaccinated during this period, he/she will be withdrawn from the study.~* Subjects suffering of a disease at the time of enrolment. 'Disease' is defined as the presence of a mild or severe illness with or without fever.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Any laboratory data collected during the screening phase found to be outside the normal range defined by the laboratory.~* Positive test for HIV, and evidence of HBV or HCV.~* Pregnant or breast-feeding women.~* History of alcohol, drug or psychotropic drug abuse (which interferes with a normal lifestyle) during the previous year.~* Subjects for which follow-up is compromised due to socio-cultural, geographic or psychological reasons.~* Any other significant finding that in the opinion of the Investigator that would increase the risk of having an adverse outcome from participating in the study.~* Subjects that are participating or have participated in another clinical trial in the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- HHD O1-EPA plus adjuvant (Type: EXPERIMENTAL): 10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
- HHD O1-EPA (Type: EXPERIMENTAL): 10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
- LHD O1-EPA adjuvanted (Type: EXPERIMENTAL): 2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
- LHD O1-EPA (Type: EXPERIMENTAL): 2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete